Study #2022-0660
A first-in-human (FIH) study of IDRX-42 in participants with metastatic and/or unresectable gastrointestinal stromal tumors (GIST)
MD Anderson Study Status
Enrolling
Treatment Agent
IDRX-42
Description
This is the first clinical trial of IDRX-42. The study is designed to evaluate the safety, tolerability, PK, and preliminary antitumor activity of IDRX-42 in adult participants with advanced (metastatic and/or surgically unresectable) GIST.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Gastrointestinal Stromal Tumor (GIST), Digestive System Disease, Gastrointestinal Diseases, Metastatic Cancer
Study phase:
Phase I
Physician name:
Neeta Somaiah
Department:
Sarcoma Medical Oncology
For general questions about clinical trials:
1-866-758-1743
Help #EndCancer
Give Now
Your gift will help make a tremendous difference.
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.